Kirsten Morley

Prof. Kirsten Morley


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MPMimi Pierce
Mimi Pierce
ASArjen Sutterland
Arjen Sutterland
EBEsther M. Beraha
Esther M. Beraha
KMKirsten Morley
Kirsten Morley
WBWim van Den Brink
Wim van Den Brink

1 September 2006 in Addiction
Verified
Journal Article
Closed access
PDF file
KMKirsten Morley
Kirsten Morley
MTMaree Teesson
Maree Teesson
SRSophie C. Reid
Sophie C. Reid
CSClaudia Sannibale
Claudia Sannibale
CTClare Thomson
Clare Thomson
PHPaul S. Haber
Paul S. Haber

1 October 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
CAClaire Adams
Claire Adams
JCJames H. Conigrave
James H. Conigrave
JLJoanne Lewohl
Joanne Lewohl
PHPaul Haber
Paul Haber
KMKirsten Morley
Kirsten Morley

3 October 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
GHGlenn E Hunt
Glenn E Hunt
NSNandi Siegfried
Nandi Siegfried
KMKirsten Morley
Kirsten Morley
TSThiagarajan Sitharthan
Thiagarajan Sitharthan
MCMichelle Cleary
Michelle Cleary

2 May 2018 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
KMKirsten Morley
Kirsten Morley
ABAndrew Baillie
Andrew Baillie
IFIsabel Fraser
Isabel Fraser
AFAinsley Furneaux-Bate
Ainsley Furneaux-Bate
GDGlenys Dore
Glenys Dore
PHPaul S. Haber
Paul S. Haber
Background: There are no available medications for the management of alcohol dependence for patients with alcoholic liver disease (ALD).Aims: To conduct a multisite, double blind, placebo-controlled, randomised clinical trial of baclofen in the treatment of alcohol dependence, with or without liver disease (trial registration: ClinicalTrials.gov, NCT01711125).Method: Patients (n= 104) were randomised to placebo, baclofen 30 mg/day or 75 mg/day for 12 weeks. Primary outcomes included survival time to lapse (any drinking), relapse (≥5 drinks per day in men and ≥4 in women), and the composite outcome of drinks per drinking day, number of heavy drinking days, and percentage days abstinent.Results: There was a significant effect of baclofen (composite groups) on time to lapse (χ2= 6.44,P<0.05, Cohen'sd= 0.56) and relapse (χ2= 4.62,P<0.05,d= 0.52). A significant treatment effect of baclofen was observed for percentage days abstinent (placebo 43%, baclofen 30 mg 69%, baclofen 75 mg 65%;P<0.05). There was one serious adverse event (overdose) directly related to medication (75 mg).Conclusions: Baclofen may be an effective treatment option for patients with ALD. However, given the profile of adverse events, the role for this medication might be best limited to specialist services.Declaration of interest: None.

7 April 2017 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
KMKirsten Morley
Kirsten Morley
JCJennifer Cornish
Jennifer Cornish
AFAlon Faingold
Alon Faingold
KWKatie Wood
Katie Wood
PHPaul S. Haber
Paul S. Haber
Introduction: Methamphetamine use is a serious public health concern in many countries and is second to cannabis as the most widely abused illicit drug in the world. Effective management for methamphetamine dependence remains elusive and the large majority of methamphetamine users relapse following treatment. Areas covered: Progression in the understanding of the pharmacological basis of methamphetamine use has provided us with innovative opportunities to develop agents to treat dependence. The current review summarizes relevant literature on the neurobiological and clinical correlates associated with methamphetamine use. We then outline agents that have been explored for potential treatments in preclinical studies, human laboratory phase I and phase II trials over the last ten years. Expert opinion: No agent has demonstrated a broad and strong effect in achieving MA abstinence in Phase II trials. Agents with novel therapeutic targets appear promising. Advancement in MA treatment, including translation into practice, faces several clinical challenges.